BCAB (BioAtla) GF Score : 25/100 (As of Mar. 24, 2025)

View and export this data going back to 2020. Start your Free Trial

What is BioAtla GF Score?

BioAtla has the GF Score of 25, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes BioAtla might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of BioAtla's GF Score

For the Biotechnology subindustry, BioAtla's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioAtla's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioAtla's GF Score distribution charts can be found below:

* The bar in red indicates where BioAtla's GF Score falls into.

BioAtla (NAS:BCAB) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

BioAtla GF Score Related Terms

Thank you for viewing the detailed overview of BioAtla's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

BioAtla Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioAtla Inc (NAS:BCAB) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

11085 Torreyana Road, San Diego, CA, USA, 92121

Website

https://www.bioatla.com

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Executives

Sylvia Mcbrinn	director
Short Jay M Phd	director, 10 percent owner, officer: Chief Executive Officer	C/O DIVERSA CORPORATION, 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Christian Vasquez	officer: See Remarks	121 E. PALOMAR STREET, CHULA VISTA CA 91911
Lawrence Steinman	director	10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Eddie Williams	director	260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Scott Andrew Smith	director, officer: President	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Eric Sievers	officer: Chief Medical Officer	11085 TORREYANA ROAD, SAN DIEGO CA 92121
Richard A Waldron	officer: Chief Financial Officer	901 MARINERS ISLAND BLVD STE.205, SAN MATEO CA 94404
Guy Levy	director, 10 percent owner	C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Soleus Pe Gp I, Llc	10 percent owner	104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Himalaya Parent Llc	10 percent owner	11085 TORREYANA ROAD, SAN DIEGO CA 92121
Susan Moran	director	1232 RICHARDSON AVE, LOS ALTOS CA 94024
Carolyn Anderson Short	10 percent owner, officer: See Remarks	11085 TORREYANA ROAD, SAN DIEGO CA 92121
Priyanka Belawat	director	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142